Bank Julius Baer & Co. Ltd, Zurich Cellectar Biosciences, Inc. Transaction History

Bank Julius Baer & Co. Ltd, Zurich

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	SELL	$8.2 - $12.4 $62,016 - $93,781	-7,563 Closed	0 $0
Q2 2021 Jul 23, 2021	BUY	$11.8 - $18.2 $743 - $1,146	63 Added 0.84%	7,563 $9,000
Q1 2021 May 10, 2021	BUY	$15.2 - $25.0 $114,000 - $187,500	7,500 New	7,500 $12,000

Ticker CLRB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 6,114,290
Market Cap $12.5M
Description
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's ma...

Get notified when there are updates to the investment portfolio of Bank Julius Baer & Co. Ltd, Zurich, based on Form 13F filings with the SEC.

Stay updated on Bank Julius Baer & Co. Ltd, Zurich with notifications on news.